Board of Visitors leadership welcomes new...
The University of Texas MD Anderson Cancer Center Board of Visitors (BOV), a nonfiduciary, appointed advisory board of volunteers who advance the institution’s mission to end cancer, marks the beginning of Fiscal Year 2019 with nine new members, effective Sept. 1:
$50 million awarded by CPRIT to MD Anderson and its projects
The University of Texas MD Anderson Cancer Center today was awarded $30 million to support research, core facilities, recruitment and...
Combination immunotherapy shrinks melanoma brain metastases
Combination immunotherapy shrank melanoma that has spread to the brain in more than half of the patients in a clinical trial reported...
PARP inhibitor improves progression-free...
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
The results of the EMBRACA trial were published today in the New England Journal of Medicine...
MD Anderson ranked No. 1 for cancer care in national survey
The University of Texas MD Anderson Cancer Center again has been ranked No. 1 for cancer care by U.S. News & World Report’s annual...
MD Anderson and Accelerator Life Science Partners launch...
The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners, a leading life science investment and...
MD Anderson and Jazz Pharmaceuticals collaborate to evaluate...
The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year collaboration agreement...
Comprehensive CAR T-cell therapy pediatric guidelines developed by...
Almost one year after the U.S. Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for...